Company Overview and News


Add DRREDDY
to your dashboard

Headline News

Shares succumb to broader selling pressure

2017-08-18 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

Sensex shuts shop above 32,000 in quiet trade

2017-07-14 indiainfoline
Key benchmark indices finished last trading day of the week with small losses in a quiet session of trade. The barometer index, the S&P BSE Sensex, fell 16.63 points or 0.05% to settle at 32,020.75. The Nifty index fell 5.35 points or 0.05% to settle at 9,886.35. The Sensex settled above the psychological 32,000 level after alternately swinging above and below that level during the day.

Market provisionally ends with tiny losses

2017-07-14 indiainfoline
Key benchmark indices provisionally settled with small losses in a quiet session of trade. The barometer index, the S&P BSE Sensex, fell 16.63 points or 0.05% at 32,020.75, as per the provisional closing data. The Nifty index fell 5.35 points or 0.05% at 9,886.35, as per the provisional closing data. The Sensex provisionally settled above the psychological 32,000 level after alternately swinging above and below that level during the day.

Update On Aralez Pharmaceuticals

2017-07-06 seekingalpha
As well, Yosprala sales have improved following recent marketing and pricing strategy changes, but remain a question mark.

Dr Reddys Laboratories intimates of completion of USFDA audit of Srikakulam Plant (SEZ) Unit I

2017-06-16 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Pharma stocks witness selling pressure

2017-06-16 indiainfoline
Ten pharma stocks fell by 0.07% to 11.22% at 14:00 IST on BSE after a media report indicated likely new US order to lower drug costs in the US.

Sensex gains for second straight day

2017-06-14 indiainfoline
Key benchmark indices garnered modest gains after gyrating in a small range during the day as firmness in most global stocks and data showing wholesale price inflation easing in May, supported gains on the bourses. The barometer index, the S&P BSE Sensex, rose 52.42 points or 0.17% to settle at 31,155.91. The Nifty 50 index rose 11.25 points or 0.12% to settle at 9,618.15. The Sensex rose for the second straight day.

Market hits fresh intraday high

2017-06-14 indiainfoline
Key benchmark indices extended gains and hit fresh intraday high in mid-afternoon trade. At 14:30 IST, the barometer index, the S&P BSE Sensex, was up 62.26 points or 0.2% at 31,165.75. The Nifty 50 index was up 5.90 points or 0.06% at 9,612.80. Index heavyweights Reliance Industries, ICICI Bank and L&T led the upmove on the domestic bourses. IT stocks fell. Most pharma shares also declined.

Dr Reddys gains after USFDA clearance for plant

2017-06-14 indiainfoline
Dr Reddys Laboratories rose 1.75% to Rs 2,674.05 at 9:16 IST on BSE after the company said it has received Establishment Inspection Report from the US drug regulator for its Miryalaguda API unit.

Pharma stocks in demand

2017-06-08 indiainfoline
Key indices were trading near the flat with tiny losses in mid-afternoon trade. At 14:20 IST, the barometer index, the S&P BSE Sensex was down 3.27 points or 0.01% at 31,268.01. The Nifty 50 index declined 0.85 points or 0.01% at 9,660. Indices hovered in a narrow range so far as investors maintained caution ahead of key global events of elections in the UK and the European Central Banks monetary policy review.

Dr Reddys Laboratories announces launch of Bivalirudin for Injection in the U.S. Market

2017-06-06 indiainfoline
Dr Reddy’s Laboratories Limited, through a BSE filing on Tuesday announced that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for Injection, approved by the US Food and Drug Administration (USFDA).

Cipla sharpens focus on core therapies

2017-05-31 business-standard
Cipla, the pharmaceuticals major, is exiting non-core businesses to build a stronger pipeline in its key therapies on offer, of respiratory, oncology and anti-HIV drugs. This comes at a time when it faces pricing pressure in both India and America. The move will mean more capital for key growth areas and reduce investment risk.

Market turns range bound

2017-05-31 indiainfoline
Key benchmark indices were range bound in afternoon trade. At 13:19 IST, the barometer index, the S&P BSE Sensex rose 34.93 points or 0.11% at 31,194.33. The Nifty 50 index advanced 10.30 points or 0.11% at 9,634.85.

Key benchmarks continue range-bound trading

2017-05-30 indiainfoline
Key benchmark indices were range bound in afternoon trade. At 13:20 IST, the barometer index, the S&P BSE Sensex was up 48.99 points or 0.16% at 31,158.27. The Nifty 50 index rose 11.50 points or 0.12% at 9,616.40. Hopes of timely arrival of monsoon rains aided small gains on the bourses.

Key benchmarks hover in green

2017-05-24 indiainfoline
Key benchmark indices were hovering in positive terrain in morning trade. At 10:21 IST, the barometer index, the S&P BSE Sensex, was up 119.53 points or 0.39% at 30,484.78. The Nifty 50 index was up 25 point, or 0.27% at 9,411.15.

Dr Reddys Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

2017-05-17 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Market extends intraday losses

2017-05-12 indiainfoline
Key indices extended intraday losses and hit fresh intraday low in mid-afternoon trade. At 14:20 IST, the barometer index, the S&P BSE Sensex was down 95.28 points or 0.31% at 30,155.70. The Nifty 50 index fell 34.25 points or 0.36% at 9,388.15. Capital goods and pharma stocks dropped.

Dr. Reddy's Laboratories Ltd.???s And Integra LifeSciences Enter Into An Agreement To Market And Distribute Duragen Plus And Suturable Duragen Dural Regeneration In India

2017-03-27 devicespace
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that they have entered into an exclusive distribution agreement. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration Matrices for use in patients in India.

CytoSorbents Announces Partnership With Dr. Reddy's Laboratories Ltd.

2017-03-17 devicespace
MONMOUTH JUNCTION, N.J., March 16, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal blood purification therapy that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients, announced today that they have entered into a partnership with Dr. Reddy's Laboratories Ltd for the South African market.

Teva Divests Eight Products to Dr. Reddy's Laboratories Ltd.'s for $350 Million

2016-06-13 biospace
HYDERABAD, India & PRINCETON, N.J--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (BSE:500124, NSE:DRREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan’s generics business.